Physician profile
Robert Timothy Pace
NPI 1326030040
$1,962.58
in general payments reported to CMS, 2019-2025
27 companies · $54.17 in 2025
The $54.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $191 · 2021: $26.92 · 2022: $172 · 2023: $40.57 · 2025: $54.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $213.95 | 2019 | |
| Novo Nordisk INC | $203.93 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $174.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $167.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.69 | 2019 | |
| Astellas Pharma US INC | $133.83 | 2019 | |
| Pfizer INC. | $130.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $130.11 | 2019-2022 | |
| Amgen INC. | $68.13 | 2019-2020 | |
| Abbvie INC. | $67.38 | 2019-2021 | |
| Lilly USA, LLC | $59.10 | 2019 | |
| Sanofi Pasteur INC. | $55.55 | 2019-2020 | |
| Genentech USA, INC. | $51.13 | 2022 | |
| Glaxosmithkline, LLC. | $49.61 | 2019 | |
| Emd Serono, INC. | $46.30 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $40.89 | 2019 | |
| Allergan, INC. | $37.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.69 | 2019 | |
| Sumitomo Pharma America, INC. | $23.34 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $22.26 | 2020 | |
| Acadia Pharmaceuticals INC | $17.23 | 2023 | Nuplazid |
| Metuchen Pharmaceuticals | $16.50 | 2019 | |
| Biogen, INC. | $16.00 | 2025 | Vumerity, Tysabri |
| Hologic Sales and Service, LLC | $15.67 | 2019 | |
| Hikma Pharmaceuticals USA | $14.72 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.